US approves new HIV drug

May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

Made by the New Jersey based Tibotec Therapeutics, Edurant helps block the virus from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.

The pill is to be taken once daily with food, the FDA said.

"Patients may respond differently to various or experience varied side effects," said Edward Cox, director of the office of antimicrobial products in the FDA's Center for Drug Evaluation and Research.

"FDA's approval of Edurant provides an additional treatment option for patients who are starting ."

The approval followed phase II and II trials that showed that patients who had not received previous therapy saw an 83 percent lower viral load after they took Edurant along with other antiretroviral drugs.

Side effects included depression, insomnia, headache and rash.

Explore further: FDA approves antiretroviral drug

Related Stories

FDA approves antiretroviral drug

August 7, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

FDA OKs Ixempra for advanced breast cancer

October 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.